Contact
searchSearch
HMP Global

Obesity

News
Obesity Treatments Project Long-Term Social Value for US Employers and Employees
09/25/2026
Rebecca Amrick
Researchers found that evidence-based obesity treatments may reduce chronic disease while generating long-term medical savings, productivity gain, and positive returns on investment among commercially insured US adults.
Researchers found that evidence-based obesity treatments may reduce chronic disease while generating long-term medical savings, productivity gain, and positive returns on investment among commercially insured US adults.
Researchers found that...
09/25/2026
First Report Managed Care
News
Higher Out-of-Pocket Costs Linked to Lower Semaglutide Adherence in Obesity
09/23/2026
Hannah Musick
Higher out-of-pocket costs were associated with lower semaglutide adherence among commercially insured adults with obesity, with nonadherence increasing more substantially when costs exceeded approximately $75 per 30-day supply.
Higher out-of-pocket costs were associated with lower semaglutide adherence among commercially insured adults with obesity, with nonadherence increasing more substantially when costs exceeded approximately $75 per 30-day supply.
Higher out-of-pocket costs were...
09/23/2026
First Report Managed Care
News
Tirzepatide Associated With Decreased Health Care Utilization and Spending Among Patients With Obesity
09/22/2026
Rebecca Amrick
Consistent adherence to tirzepatide was associated with lower per-person-per-month costs and reduced health care utilization compared to no treatment among patients with obesity or overweight, according to an article published in Diabetes,...
Consistent adherence to tirzepatide was associated with lower per-person-per-month costs and reduced health care utilization compared to no treatment among patients with obesity or overweight, according to an article published in Diabetes,...
Consistent adherence to...
09/22/2026
First Report Managed Care
News
GLP-1 Coverage Linked to Higher Utilization and Costs in Employer-Sponsored Health Plans
09/17/2026
Rebecca Amrick
Researchers found that between 2021 and 2024, utilization of glucagon-like peptide-1 (GLP-1) medications increased among patients with obesity, with greater growth among plans providing coverage for GLP-1 drugs.
Researchers found that between 2021 and 2024, utilization of glucagon-like peptide-1 (GLP-1) medications increased among patients with obesity, with greater growth among plans providing coverage for GLP-1 drugs.
Researchers found that between...
09/17/2026
First Report Managed Care
News
Significant Care Costs for Obesity Medications Associated With High Rates of Treatment Discontinuation
09/08/2026
Rebecca Amrick
Researchers found that newer obesity medications were associated with higher drug and total care costs as well as nonsignificant changes in health care utilization compared to phentermine, raising concerns about access for patients with...
Researchers found that newer obesity medications were associated with higher drug and total care costs as well as nonsignificant changes in health care utilization compared to phentermine, raising concerns about access for patients with...
Researchers found that newer...
09/08/2026
First Report Managed Care
News
US Study Identifies Factors Linked to Low Metabolic Bariatric Surgery Uptake
07/24/2026
Grace Taylor, MS, MA
A large US cohort study found that only 3% of adults newly diagnosed with obesity underwent metabolic bariatric surgery within one year, with provider type, body mass index, sex, and other clinical factors strongly influencing access to...
A large US cohort study found that only 3% of adults newly diagnosed with obesity underwent metabolic bariatric surgery within one year, with provider type, body mass index, sex, and other clinical factors strongly influencing access to...
A large US cohort study found...
07/24/2026
First Report Managed Care
News
Obesity Subphenotype With Low GLP-1 Levels Shows Greater Weight Loss With Tirzepatide
07/21/2026
Hannah Musick
Researchers identified an obesity subphenotype characterized by rapid gastric emptying and low endogenous GLP-1 production that achieved nearly twice the weight loss with tirzepatide as other obesity phenotypes, highlighting the potential for...
Researchers identified an obesity subphenotype characterized by rapid gastric emptying and low endogenous GLP-1 production that achieved nearly twice the weight loss with tirzepatide as other obesity phenotypes, highlighting the potential for...
Researchers identified an...
07/21/2026
First Report Managed Care
News
Real-World Data Show Semaglutide’s Impact on Health Care Utilization and Medical Costs for Patients With OW/OB
04/17/2026
Rebecca Amrick
A large observational study of a US administrative claims database examined the effects of semaglutide on health care resource utilization (HCRU) and medical costs in patients with overweight or obesity (OW/OB) and multimorbidity.
A large observational study of a US administrative claims database examined the effects of semaglutide on health care resource utilization (HCRU) and medical costs in patients with overweight or obesity (OW/OB) and multimorbidity.
A large observational study of a...
04/17/2026
First Report Managed Care
News
Semaglutide Promotes Fat Loss While Preserving Muscle Function in Severe Obesity
03/13/2026
Lisa Kuhns, PhD, MD
A real-world study suggests semaglutide not only drives meaningful weight loss but may also improve muscle strength and reduce sarcopenic obesity in patients with severe obesity.
A real-world study suggests semaglutide not only drives meaningful weight loss but may also improve muscle strength and reduce sarcopenic obesity in patients with severe obesity.
A real-world study suggests...
03/13/2026
First Report Managed Care
News
NHANES Data Highlight Growing Severe Obesity Burden in US Adults
03/05/2026
Grace Taylor, MS, MA
New National Health and Nutrition Examination Survey (NHANES) data show that more than 40% of U.S. adults have obesity, with severe obesity continuing to rise and persistent disparities across age, sex, and racial groups.
New National Health and Nutrition Examination Survey (NHANES) data show that more than 40% of U.S. adults have obesity, with severe obesity continuing to rise and persistent disparities across age, sex, and racial groups.
New National Health and...
03/05/2026
First Report Managed Care
Industry Insights
News
First Report Managed Care

Current Issue

September 2026
Volume 23
Issue 3
Current Issue
Issue Archive

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use